Bio-Techne (TECH) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TECH Bio-Techne

Watchlist

73.370
+2.410+3.40%

Close Aug 8 16:00 ET

74.000
+0.630+0.86%

Post 17:28 ET

11.56BMarket Cap69.88P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $70
Benzinga15:51 ET
Citigroup Adjusts Price Target on Bio-Techne to $80 From $85
MT NewswiresAug 8 09:41 ET · Ratings
Express News | Baird Maintains Outperform on Bio-Techne, Raises Price Target to $82
BenzingaAug 8 08:01 ET
Bio-Techne Analyst Ratings
BenzingaAug 8 08:00 ET · Ratings
RBC Capital Keeps Their Hold Rating on Bio-Techne (TECH)
TipRanksAug 8 07:57 ET · Ratings
Express News | Bio-Techne Corp : RBC Cuts Target Price to $70 From $72
ReutersAug 8 03:49 ET

Comments

Trytosaveabit

May 22 06:21

Update

$Regulus Therapeutics (RGLS.US)$ $Bio-Techne (TECH.US)$ Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Moomoo AI

Dec 28, 2023 05:17

Despite Bio-Techne's high P/E ratio, the lower forecast growth potentially overvalues it. Investors may risk a share price decline due to weak earnings outlook, posing a risk for those holding onto shares.